

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力農本方有限公司

(Formerly known as 培力控股有限公司 in Chinese)

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Reference is made to the annual report of PuraPharm Corporation Limited (the “**Company**”) for the year ended 31 December 2020 (the “**Annual Report**”). The board of directors (the “**Directors**”) of the Company would like to provide additional information to the Annual Report in relation to the share option scheme of the Company adopted on 12 June 2015 (the “**Share Option Scheme**”) that the period within which payments or calls must or may be made or loans for such purposes must be repaid for the amount payable on acceptance of the option under the rules of the Share Option Scheme is 30 days after the relevant date of grant of the options.

The above supplementary information does not affect any other information contained in the Annual Report and all other information in the Annual Report remains unchanged.

By order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman

Hong Kong, 8 October 2021

As at the date of this announcement, the executive Directors are Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola and Dr. Norimoto Hisayoshi; the non-executive Directors are Mr. Chow, Stanley and Mr. Cheong Shin Keong; and the independent non-executive Directors are Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.